Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer.

Katrin M Sjoquist,Andrew Martin,Nick Pavlakis,David Goldstein,Eric Tsobanis,Daniel Moses,Richard Maher,Wendy Hague,Val Gebski,Martin R Stockler,R John Simes

Journal of cancer research and clinical oncology（2022）

引用 0|浏览15

暂无评分

摘要

Blinded independent central review was feasible and supported the reliability of site assessments, trial results, and conclusions. Modelling showed that when treatment effects were large and outcome assessments blinded, central review was unlikely to affect conclusions.

查看译文

关键词

Clinical trial,Oesophageal cancer,Progression-free survival,Response evaluation criteria in solid tumours,Treatment effectiveness

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要